Cellectis Reports Q4 2025 and FY 2025 Financial Results and Business Update

Cellectis reported Q4 2025 and FY 2025 financial results, highlighting promising efficacy of lasmé-cel in a complex oncology context, with a 100% response rate in phase 2 target population. The phase 2 pivot trial is ongoing, and a BLA is expected in 2028. Eti-cel, a "best-in-class" CAR-T allogeneic double-targeting CD20 and CD22, showed 88% ORR and 63% CR in phase 1 for relapsed/refractory NHL. The company's partnerships with Servier and AstraZeneca are progressing, and its treasury stands at $211 million as of December 31, 2025.